Treatment of these cells with either ibrutinib or AZD2014 inhibited luciferase activity, confirming that both BTK and mTOR are upstream regulators of this pathway in DLBCL (Fig 3E). Here, MTOR is linked to diffuse large B-cell lymphoma.